Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR
- 438 Downloads
To evaluate the ability of late gadolinium enhancement (LGE) and mapping cardiac magnetic resonance (CMR) including native T1 and global extracellular volume (ECV) to identify hypertrophic cardiomyopathy (HCM) patients at risk for sudden cardiac death (SCD) and to predict syncope or non-sustained ventricular tachycardia (VT).
A 1.5-T CMR was performed in 73 HCM patients and 16 controls. LGE size was quantified using the 3SD, 5SD and full width at half maximum (FWHM) method. T1 and ECV maps were generated by a 3(3)5 modified Look-Locker inversion recovery sequence. Receiver-operating curve analysis evaluated the best parameter to identify patients with increased SCD risk ≥4% and patients with syncope or non-sustained VT.
Global ECV was the best predictor of SCD risk with an area under the curve (AUC) of 0.83. LGE size was significantly inferior to global ECV with an AUC of 0.68, 0.70 and 0.70 (all P < 0.05) for 3SD-, 5SD- and FWHM-LGE, respectively. Combined use of the SCD risk score and global ECV significantly improved the diagnostic accuracy to identify HCM patients with syncope or non-sustained VT.
Combined use of the SCD risk score and global ECV has the potential to improve HCM patient selection, benefiting most implantable cardioverter defibrillators.
• Global ECV identified the best HCM patients with increased SCD risk.
• Global ECV performed equally well compared to a SCD risk score.
• Combined use of the SCD risk score and global ECV improved test accuracy.
• Combined use potentially improves selection of HCM patients for ICD implantation.
KeywordsHypertrophic cardiomyopathy Prognosis Late gadolinium enhancement Extracellular volume Risk assessment
Cardiac magnetic resonance
Estimated glomerular filtration rate
Full width half maximum
Implantable cardioverter defibrillator
Late gadolinium enhancement
Left ventricular ejection fraction
Left ventricular outflow tract
N-terminal pro b-type natriuretic peptide
New York Heart Association
Modified Look-Locker inversion recovery
Sudden cardiac death
Compliance with ethical standards
The scientific guarantor of this publication is Gunnar K. Lund.
Conflict of interest
The authors of this manuscript declare relationships with the following companies: Philips Research, Hamburg, Germany.
Dr. Stehning is an employee of Philips Research, Hamburg, Germany.
The authors state that this work has not received any funding.
Statistics and biometry
One of the authors has significant statistical expertise.
Institutional Review Board approval was obtained.
Written informed consent was obtained from all subjects (patients) in this study.
• diagnostic or prognostic study
• performed at one institution
- 4.Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMedGoogle Scholar
- 5.Ruiz-Salas A, García-Pinilla J, Cabrera-Bueno F, et al. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2015:3–7. doi: 10.1093/europace/euv079
- 16.Miller CA, Naish JH, Bishop P, et al. (201 3) Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 6:373–383. doi: 10.1161/CIRCIMAGING.112.000192
- 19.Schulz-Menger J, Bluemke DA, Bremerich J et al (2013) Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing. J Cardiovasc Magn Reson 15:35CrossRefPubMedPubMedCentralGoogle Scholar
- 20.HCM Risk-SCD Calculator: Available via http://doc2do.com/hcm/webHCM.html . Accessed 15 Aug 2016
- 29.Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495.Google Scholar
- 34.Schelbert EB, Piehler KM, Zareba KM et al (2015) Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc 4, e002613. doi: 10.1161/JAHA.115.002613 CrossRefPubMedPubMedCentralGoogle Scholar